Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11955436 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Liu C, et al. (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-47 11955436
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S33-p - CTNNB1 (human) ▲
Orthologous residues
CTNNB1 (human): S33‑p, CTNNB1 (mouse): S33‑p, CTNNB1 (rat): S33‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  oocyte, Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  frog, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE GSK3A (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) transfection of dominant-negative enzyme, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium decrease
Wnt decrease
Associated Diseases
Diseases: Alterations: Comments:
colorectal cancer mutation of site

S37-p - CTNNB1 (human) ▲
Orthologous residues
CTNNB1 (human): S37‑p, CTNNB1 (mouse): S37‑p, CTNNB1 (rat): S37‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  oocyte, Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  frog, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE GSK3A (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) transfection of dominant-negative enzyme, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium decrease
Wnt decrease
Associated Diseases
Diseases: Alterations: Comments:
colorectal cancer mutation of site

T41-p - CTNNB1 (human) ▲
Orthologous residues
CTNNB1 (human): T41‑p, CTNNB1 (mouse): T41‑p, CTNNB1 (rat): T41‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  oocyte, Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  frog, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE GSK3A (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) transfection of dominant-negative enzyme, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium decrease
Wnt decrease
Associated Diseases
Diseases: Alterations: Comments:
colorectal cancer mutation of site

S45-p - CTNNB1 (human) ▲
Orthologous residues
CTNNB1 (human): S45‑p, CTNNB1 (mouse): S45‑p, CTNNB1 (rat): S45‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  oocyte, Rat2 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  frog, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK1A (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK1A (rat) siRNA inhibition of enzyme, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium increase
Wnt no change compared to control
Downstream Regulation
 Effect of modification (function):  molecular association, regulation, phosphorylation, protein degradation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
axin 1 (human) Induces electrophoretic visualization, co-immunoprecipitation
 Comments:  CK1-A phosphorylation of S45 is required for CTNNB1 degradation and Arm degradation in drosophilla.
Associated Diseases
Diseases: Alterations: Comments:
colorectal cancer mutation of site


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.